Remove 2023 Remove Physicians Remove Prescription
article thumbnail

Instant Insights – Weight Loss Drugs

InCrowd

Prescriber Perspectives on Weight Loss Drugs in 2023 Examine how healthcare professionals (HCPs) view and prescribe weight loss drugs currently on the market in our new Instant Insights report. Download the report today. The post Instant Insights – Weight Loss Drugs appeared first on InCrowd.

article thumbnail

The Weight Loss Medication Dilemma: A Physician’s Perspective

PM360

Survey any physician if they’ve been asked by a patient about a prescription weight loss medication and you’ll hear a resounding “yes.” The recent Sermo Barometer confirms that 89% of 300+ global practitioners have seen an increase in patients proactively requesting prescription weight loss medications.

Medical 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Curavit’s crystal ball – how will 2023 drive meaningful changes in clinical research

pharmaphorum

As this collective body of experience continues to proliferate, 2023 will see additional FDA guidance. In 2023, expect to see AI innovations improve enrolment agility and, most importantly, the patient experience in a clinical trial. Beyond 2023 – the Sovereign Patient ID.

FDA 97
article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

Indeed, Amgen’s biosimilar was approved in September 2016, but the company was not able to launch it until January 2023 in the US. In September 2017, Amgen announced that it reached a global settlement with AbbVie, scheduling Amjevita’s American launch for January 31, 2023. Humira biosimilars became available in the EU in October 2018.

Marketing 104
article thumbnail

Use Your Physician Directory to Increase Patient Conversion

LEVO Health

One way to do this is through a physician directory. Physician directories allow consumers to discover and compare provider ratings and reviews. Healthcare and pharmaceutical brands are expected to spend 15 billion dollars on digital advertising in 2023 and for a good reason.

article thumbnail

Two Key Questions About Adherence/Compliance in 2023

PM360

These discussions can be initiated by HCPs ranging from physicians to advanced practice professionals. What if the industry were to incentivize persistence over new prescriptions? Facilitating this level of communication can foster concordance and ultimately drive desirable clinical outcomes.

Medical 98
article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. On the other side, drug manufacturers are facing the squeeze, with caps on price inflation and a mandated 20% discount in the catastrophic phase.